Bristol Myers Squibb Presents Value Case Amid Patent Cliffs and Debt Concerns

Bristol Myers Squibb (BMY) is positioning itself as a primary target for value investors, characterized by a low forward price-to-earnings (P/E) ratio of approximately 9.5. This valuation stands in stark contrast to industry peers such as Johnson & Johnson and Merck, which trade at forward P/E ratios of 21 and 24, respectively. The company's appeal is bolstered by a 4.2% dividend yield and a long-standing history of payouts, including 17 consecutive years of increases. Despite these strengths, BMY faces a complex transition as it attempts to replace revenue from its aging product line with new growth drivers. Financial data reveals a slight downward trend in total revenue, from $48.3 billion in 2024 to $48.2 billion in 2025, with 2026 projections ranging between $46 billion and $47.5 billion. A critical point of concern is the 'legacy portfolio,' which saw revenues drop from $25.7 billion in 2024 to $21.8 billion in 2025. Specifically, the blood thinner Eliquis, which generated $14.4 billion in 2025, is approaching a patent cliff. To counter these losses, BMY is leaning into its 'growth portfolio,' which rose from $22.6 billion in 2024 to $26.4 billion in 2025. The company is also expanding its pipeline through the $1.5 billion acquisition of Orbital Therapeutics, focusing on the RNA medicine market. While this move aims for long-term sustainability, it adds to a debt load that already exceeds $47 billion.